Small molecule · Inhibitor of orthopoxvirus VP37 (P37) · developed by Siga Technologies
Tecovirimat is an orally available small-molecule inhibitor of orthopoxvirus VP37 envelope wrapping protein that blocks viral particle release from infected cells.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Dec 31, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04485039 | Phase 4 | Smallpox | Completed | SIGA |
| NCT04392739 | Phase 4 | Smallpox | Completed | SIGA |
| NCT05534984 | Phase 3 | MPOX | Terminated | SIGA |
| NCT00907803 | Phase 2 | Orthopoxviral Disease | Completed | SIGA |
| NCT00728689 | Phase 1 | Orthopoxviral Disease | Completed | SIGA |
| NCT00431951 | Phase 1 | Healthy | Completed | SIGA |
| NCT03972111 | N/A | Smallpox | Withdrawn | SIGA |
| NCT05380752 | N/A | Orthopox Virus Infection | No longer available | SIGA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
HealthyMonkey PoxMPOXOrthopox Virus InfectionOrthopoxviral DiseaseSmallpox
Updated Oct 3, 2026. Something wrong or missing? Report it on the SIGA page.
See SIGA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SIGA catalysts and pipeline →